All Stories

  1. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development
  2. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound
  3. Evaluation of drug-drug interactions for oncology therapies:in vitro-in vivoextrapolation model-based risk assessment
  4. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
  5. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
  6. Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652
  7. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension
  8. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor
  9. Computational Approaches in Drug Biotransformation Studies: Metabolite Prediction
  10. Consideration of the Unbound Drug Concentration in Enzyme Kinetics
  11. Structure–Efficiency Relationship of [1,2,4]Triazol-3-ylamines as Novel Nicotinamide Isosteres that Inhibit Tankyrases
  12. Identification of NVP-TNKS656: The Use of Structure–Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor
  13. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance
  14. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State
  15. CHAPTER 3. High‐Resolution NMR‐Based Metabolic Profiling in Drug Discovery and Development
  16. In silico Prediction of Total Human Plasma Clearance
  17. Editorial [Hot topic: Drug Design from the ADME/PK Perspective: Does Chemical Intuition Suffice in Multifaceted Drug Discovery? (Guest Editors: Franco Lombardo & Nigel J. Waters)]
  18. The Role of Metabonomics at the Interface Between Drug Metabolism and Safety Assessment
  19. In Silico Prediction of Volume of Distribution in Human Using Linear and Nonlinear Models on a 669 Compound Data Set
  20. Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding
  21. Advancements in Predictive In Silico Models for ADME
  22. Advancements in Predictive In Silico Models for ADME
  23. Quantitative Structure Activity Relationships in Drug Metabolism
  24. Integrated Metabonomic Analysis of Bromobenzene-Induced Hepatotoxicity:  Novel Induction of 5-Oxoprolinosis
  25. In Silico Human and Rat V ss Quantitative Structure−Activity Relationship Models
  26. Metabonomics
  27. Metabonomic Deconvolution Of Embedded Toxicity:  Application To Thioacetamide Hepato- and Nephrotoxicity
  28. NMR and pattern recognition studies on liver extracts and intact livers from rats treated with α-naphthylisothiocyanate
  29. NMR and Pattern Recognition Studies on the Time-Related Metabolic Effects of α-Naphthylisothiocyanate on Liver, Urine, and Plasma in the Rat:  An Integrative Metabonomic Approach
  30. Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery